Easterly Investment Partners LLC Makes New Investment in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Easterly Investment Partners LLC purchased a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 9,558 shares of the company’s stock, valued at approximately $208,000.

Several other hedge funds and other institutional investors also recently modified their holdings of FLGT. Rhumbline Advisers lifted its position in Fulgent Genetics by 0.9% during the second quarter. Rhumbline Advisers now owns 68,210 shares of the company’s stock valued at $1,338,000 after purchasing an additional 637 shares during the last quarter. Signaturefd LLC increased its stake in Fulgent Genetics by 103.6% in the second quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock valued at $44,000 after acquiring an additional 1,132 shares during the last quarter. Marquette Asset Management LLC raised its position in Fulgent Genetics by 13.7% during the third quarter. Marquette Asset Management LLC now owns 9,908 shares of the company’s stock valued at $215,000 after purchasing an additional 1,191 shares in the last quarter. Asset Dedication LLC purchased a new stake in Fulgent Genetics during the second quarter valued at about $33,000. Finally, nVerses Capital LLC bought a new stake in Fulgent Genetics during the second quarter worth about $43,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Trading Down 11.8 %

Shares of Fulgent Genetics stock opened at $19.43 on Friday. The firm has a market capitalization of $588.73 million, a PE ratio of -3.55 and a beta of 1.51. Fulgent Genetics, Inc. has a 12 month low of $18.76 and a 12 month high of $30.68. The business’s 50-day moving average price is $21.01 and its 200-day moving average price is $21.43.

Insider Buying and Selling at Fulgent Genetics

In other news, CEO Ming Hsieh sold 2,313 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total value of $52,805.79. Following the completion of the sale, the chief executive officer now owns 707,275 shares of the company’s stock, valued at approximately $16,147,088.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 4,324 shares of company stock worth $98,717 over the last ninety days. Insiders own 32.66% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.